Navigation Links
Vanda Reports Successful Completion Of Pre-NDA Meeting With FDA On Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
Date:3/25/2013

kelly@vandapharma.com">jim.kelly@vandapharma.com

Media Contact:
Laney Cohen
Account Supervisor
Makovsky & Company, Inc.
(212)-508-9643
lcohen@makovsky.com

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "project," "target," "goal," "likely," "will," "would," and "could," or the negative of these terms and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties.  Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: the inability to reach agreement with the FDA regarding Vanda's regulatory approval strategy or proposed path to approval for tasimelteon for the treatment of Non-24-Hour Disorder; Vanda's failure to obtain regulatory approval for tasimelteon for the treatment of Non-24-Hour Disorder or to comply with ongoing regulatory requirements; and other factors that are described in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's annual report on Form 10-K for the fiscal year ended December 31, 2012 which is on file with the SEC and available on the SEC's website at www.sec.gov.  In addition to the risks described above and in Vanda's annual report on Form 10-K and quarterly reports on Form 10-Q, other unknown or unpredictable factors also could affect Vanda's results.  There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantia
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
2. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
3. Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
4. Vanda Announces Positive Results in the Second Phase III Study (RESET) of Tasimelteon for the Treatment of Non-24-Hour Disorder
5. Vanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
6. Vanda Pharmaceuticals Reports Third Quarter 2012 Results
7. Vanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
8. Vanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
9. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
10. Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals
11. Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today ... 2014.  The Company reported second quarter net sales of ... constant currency over the second quarter of 2013.  Diluted ... and $1.49 adjusted, an increase of 4.2% adjusted over ... quarter was marked by solid sales growth in a ...
(Date:7/24/2014)... 24, 2014 Cognizant ... that it has been selected by ... with membership representation from 19 major pharmaceutical ... that will transform the way clinical sites ... TransCelerate BioPharma Inc. is dedicated to making ...
(Date:7/23/2014)... ALTO, Calif., July 23, 2014  Varian Medical Systems ... earnings of $1.02 per diluted share in the third ... impacted by about $0.06 per diluted share due to ... portion of Varian,s existing equity investment in Augmenix, a ... company-wide revenues totaled $748 million for the third quarter ...
Breaking Medicine Technology:Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 14Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 15Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 16Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 17Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 18Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 19Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 20Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 21Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 23Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 24TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 2TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 3TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 4TransCelerate Selects Cognizant to Develop a Clinical Trials Collaboration Platform 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 2Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 3Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 4Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 5Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 6Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 7Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 8Varian Medical Systems Reports Results for Third Quarter of Fiscal Year 2014 9
... LOUIS, Oct. 30 Stereotaxis received notice that the ... for distribution in the European market. The product ... on-going co-development agreement between Stereotaxis and Biosense Webster to ... the Niobe Magnetic Navigation System (MNS). , A ...
... COLUMBUS, Ohio, Oct. 29 Mettler-Toledo International Inc. (NYSE: MTD ) ... the highlights: , Sales in local currency declined by ... a 2% negative currency impact. , Net earnings ... in the third quarter of 2008. Adjusted EPS was $1.36, ...
Cached Medicine Technology:Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 2Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 3Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 4Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 5Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 6Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 7Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 8Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 9Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 10Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 11Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 12Mettler-Toledo International Inc. Reports Third Quarter 2009 Results 13
(Date:7/24/2014)... (PRWEB) July 24, 2014 The North American ... $1.6 billion in 2014, and is expected to register a ... U.S. has been the biggest market for the air and ... the U.S. market has witnessed budget cuts as well. , ... missile defense radar market report, to get an idea of ...
(Date:7/24/2014)... 23, 2014 (HealthDay News) -- Even though its use is ... as Tylenol -- does not help treat lower back pain, ... found the drug was no more effective than a dummy ... back pain. Besides showing no effect in easing discomfort, ... improving sleep woes tied to back pain, nor did it ...
(Date:7/24/2014)... at emergency departments can be reduced by enabling patients ... their doctor,s surgery. This is just one of several ... researchers at the University of Bristol. , Called ,Primary ... systematic reviews, the report has been compiled by researchers ... looked at evidence from studies around the world. They ...
(Date:7/24/2014)... and Rhode Island have identified two previously ... of laparoscopically adjustable gastric bands. Adding widespread ... the superolateral band margin by more than ... presence of an air-fluid,level above the band ... will aid them in diagnosing affected bariatric ...
(Date:7/24/2014)... were found commonly in streams throughout the Midwest, ... the first broad-scale investigation of neonicotinoid insecticides in ... first conducted within the United States. , Effective ... use of neonicotinoid insecticides has dramatically increased over ... in the Midwest. The use of clothianidin, ...
Breaking Medicine News(10 mins):Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 2Health News:Acetaminophen May Not Help Against Back Pain, Study Contends 3Health News:Seeing the same GP at every visit will reduce emergency department attendance 2Health News:Corn & soy insecticides similar to nicotine found widespread in Midwest rivers -- USGS news 2
... to Create Sustainable Breast Cancer Programs in ... Countries with Highest Potential, Greatest Need, BUDAPEST, Hungary, ... receiving a breast cancer diagnosis each year, it has ... about this,life-threatening disease. Building on the U.S.-Middle East Partnership ...
... experts say , , FRIDAY, Sept. 28 (HealthDay News) -- ... autoimmune disease lupus is building up steam, a group ... researchers from across the United States spoke at a ... of the improving outlook for patients with systemic lupus ...
... According to the American Society of,Plastic ... Latinos received,physician-administered aesthetic procedures like BOTOX(R) Cosmetic ... board certified,dermatologist in Miami, says that given ... that women make informed decisions when,considering these ...
... TJ Enterprises, LLC,announced that its product, ... the treatment of baby digestive discomfort including ... the U.S. Food and Drug,Administration (FDA) confirmed ... a non-homeopathic gripe water, Apple Flavored Baby,s,Bliss, ...
... WAYNE, Pa., Sept. 28 Escalon Medical Corp.,(Nasdaq: ... quarter and,twelve months ended June 30, 2007. For ... increased,to $38,837,780 compared with $29,790,698 in fiscal 2006. This ... million lump sum settlement payment,from IntraLase Corp. to the ...
... NEW ORLEANS, Sept. 28 Sanarus Medical today ... select centers across,the country. These Centers, including breast ... partnership with Sanarus to,increase the awareness and availability ... benign breast tumors, known as,fibroadenomas. Sanarus will host ...
Cached Medicine News:Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 2Health News:Susan G. Komen for the Cure Launches Unprecedented Global Expansion Program in 10 Countries 3Health News:Better Lupus Treatments on the Horizon 2Health News:Better Lupus Treatments on the Horizon 3Health News:Better Lupus Treatments on the Horizon 4Health News:After Infant Gripe Water Recall Scare, Homeopathic Medicine Offers Safe Alternative 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 2Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 3Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 4Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 5Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 6Health News:Escalon(R) Reports Financial Results for 2007 Fiscal Year 7Health News:Sanarus Announces Partnership With Leading US Breast Care Physicians for the Next Generation Visica 2(TM) Treatment System for Fibroadenomas 2
... three styles. Each style has multiple sizes. ... popular style. Pectoral Implants are available non-sterile ... individually, not in pairs. Both styles are ... for a specific side and are directional. ...
... The IQmarkTM Diagnostic Workstation Software ... Software System that digitally stores many ... Designed with Microsofts open-architecture products in ... as EMR integration (using ActiveX controls), ...
... Digital ECG is a highly advanced and refined ... personal computer. Everything you need to get up ... and operating costs of the IQmark Digital ECG ... ECG machines (even including the cost of the ...
... Trichloroacetic acid (TCA) peels are often ... substantial discomfort. PCA Professional™ TCA peels are ... solutions are blends formulated with many ingredients ... plumping phytohormones and kojic and azelaic acids ...
Medicine Products: